Fig. 1

The sensitivity of trastuzumab in HER2-positive cancer cells and its effects on the HER2 signaling pathway. a The sensitivity of trastuzumab in HER2-positive breast cancer cells (BT474) was higher than that observed in HER2-positive gastric cancer cells (NCI-N87 and SNU216). b Phosphorylated AKT and S6 were both inhibited by trastuzumab in BT474 cells, however, only phosphorylated AKT was inhibited by trastuzumab in NCI-N87 and SNU216 cells. Proliferation assays are expressed as the Mean ± S.D of three replicate assays. Western blots were repeated at least twice. * P <0.01 according to factorial analysis. Cropped blots were used because the same experimental conditions were used for running all the gels